[1]曲波,王海琳△,吴红彦,等.参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌临床疗效分析[J].西部中医药,2017,30(08):1-4.
　QU Bo,WANG Hailin,WU Hongyan,et al.An Analysis of Clinical Effects of ShenQi Tumor-inhibiting Prescriptions Jointed with Neoadjuvant Chemotherapy in Treating Cervical Carcinoma at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2017,30(08):1-4.
点击复制

参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌临床疗效分析
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
30
期数:
2017年08期
页码:
1-4
栏目:
出版日期:
2017-08-15

文章信息/Info

Title:
An Analysis of Clinical Effects of ShenQi Tumor-inhibiting Prescriptions Jointed with Neoadjuvant Chemotherapy in Treating Cervical Carcinoma at Advanced Stage
文章编号:
1004-6852(2017)08-0001-04
作者:
曲波1，王海琳1△，吴红彦2，汪丽1
1 甘肃省人民医院，甘肃 兰州 730000； 2 甘肃中医药大学
Author(s):
QU Bo1, WANG Hailin1△, WU Hongyan2, WANG Li1
1 Gansu Provincial Hospital, Lanzhou 730000, China; 2 Gansu University of Traditional Chinese Medicine
关键词:
宫颈癌; 参芪抑瘤方; 新辅助化疗
Keywords:
cervical carcinoma;  ShenQi tumor-inhibiting prescription;  neoadjuvant chemotherapy
分类号:
R737
文献标志码:
A
摘要:
目的：观察参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌的临床疗效。方法：将60例Ⅱb～Ⅲb期宫颈癌患者随机分为观察组、对照组各30例。2组均给予新辅助化疗方案，观察组同时服用参芪抑瘤方，治疗达到手术指征。观察2组患者肿瘤直径改善状况、肿瘤转移情况、治疗前后血清免疫学细胞前后变化、对化疗的耐受情况、副反应、3年生存率及临床疗效。结果：总有效率观察组为66.7%，对照组为40.0%，2组比较差异有统计学意义(P＜0.05)；化疗时间观察组短于对照组，2组比较差异有统计学意义(P＜0.05)。肿瘤直径治疗后2组均明显缩小，与治疗前比较差异有统计学意义(P＜0.05)；治疗后组间比较差异也有统计学意义(P＜0.05)。CD3+、CD4+、CD4+/CD8+、NK细胞治疗后观察组均显著升高，差异有统计学意义(P＜0.05)；治疗后观察组无明显变化(P＞0.05)；治疗后2组组间比较，差异有统计学意义(P＜0.05)。3年生存率、局部复发率、远处转移率2组比较，差异有统计学意义(P＜0.05)。化疗耐受率观察组为93.3%，对照组为83.3%，2组比较差异无统计学意义（P＞0.05）。血小板减少情况及白细胞减少情况，2组比较差异无统计学意义（P＞0.05）。结论：参芪抑瘤方有助于提高新辅助化疗疗效，减少化疗周期，提升患者免疫水平，提高治疗耐受性及依从性。
Abstract:
Objective: To survey clinical effects of ShenQi tumor-inhibiting prescriptions jointed with neoadjuvant chemotherapy in treating cervical carcinoma at advanced stage. Methods: Sixty patients were randomized into the observation group and the control group, 30 cases each group. Both groups were given with neoadjuvant chemotherapy, the observation group took ShenQi tumor-inhibiting prescription simultaneously, and the treatment reached the operation indications. Clinical effects, survival rate within three years, adverse reaction, the tolerance conditions of chemotherapy, and the changes of serum immune cells before and after treating, tumor metastasis, as well as the improvements of tumor diameters of both groups were observed. Results: Total effective rate of the observation group was 66.7%, higher than 40.0% of the control group, and the difference had statistical meaning(P＜0.05); the observation group was shorter than the control group in the chemotherapy time, and the difference showed statistical meaning (P＜0.05). Tumor diameters of both groups decreased obviously after treating, and the difference had statistical meaning compared with before treating (P＜0.05); the difference had statistical meaning between both groups after treating (P＜0.05). The numbers of CD3+, CD4+, CD4+/ CD8+ and NK cells of the observation group raised significantly after treating, and the difference had statistical meaning (P＜0.05); there was no obvious changes in the observation group after treating (P＞0.05); the difference had statistical meaning in the comparison between both groups after treating (P＜0.05). The difference had statistical meaning in the comparisons of survival rate within three years, local relapse rate and distant metastasis rate between both groups (P＜0.05). The tolerance rate of chemotherapy of the observation group was 93.3%, higher than 83.3% of the control group, and the difference had no statistical meaning between both groups (P＞0.05). The difference had no statistical meaning in the comparisons of thrombopenia and aleukocytosis conditions (P＞0.05). Conclusion: ShenQi tumor-inhibiting prescription is helpful to improve clinical effects of neoadjuvant chemotherapy, reduce chemotherapy cycle, and improve the immunity of the patients as well as therapeutic tolerance and compliances.

相似文献/References:

[1]樊慧妮.心理护理对宫颈癌患者生活质量的影响[J].西部中医药,2014,27(10):138.
[2]郭强蕊.CT诊断在卵巢癌和宫颈癌放射治疗前后的临床运用价值[J].西部中医药,2015,28(01):125.
[3]邵金博.郭立中应用“温阳法”保守治疗宫颈癌验案分析*[J].西部中医药,2014,27(06):37.
　SHAO Jinbo.On Professor Guo Lizhong′s Experience of Applying Conservative Therapy of "Yang-warming Method" to Cervical Carcinoma[J].Western Journal of Traditional Chinese Medicine,2014,27(08):37.
[4]关崇丽,郑婧,王惠玲△.丹参酮ⅡA对人宫颈癌细胞增殖与凋亡的影响[J].西部中医药,2020,33(01):37.[doi:10.12174/j.issn.1004-6852.2020.01.10]
　GUAN Chongli,ZHENG jing,WANG Huiling.Effect of Tanshinone Ⅱ A on the Proliferation and Apoptosis of Human Cervical Cancer Cells[J].Western Journal of Traditional Chinese Medicine,2020,33(08):37.[doi:10.12174/j.issn.1004-6852.2020.01.10]
[5]李娟,何春晓,刘冬梅.中药封包联合盐酸坦洛新对宫颈癌术后尿潴留的防治[J].西部中医药,2020,33(02):120.[doi:10.12174/j.issn.1004-6852.2020.02.34]
　LI Juan,HE Chunxiao,LIU Dongmei.TCM Package Joined with Tamsulosin Hydrochloride in the Prevention and Treatment for Urinary Retention after the Surgery of Cervical Carcinoma[J].Western Journal of Traditional Chinese Medicine,2020,33(08):120.[doi:10.12174/j.issn.1004-6852.2020.02.34]
[6]陈静,褚福浩,金珠措姆,等.藏药普尔那提取物对宫颈癌海拉细胞增殖作用的研究[J].西部中医药,2021,34(06):18.[doi:10.12174/j.issn.2096-9600.2021.06.05]
　CHEN Jing,CHU Fuhao,Jinzhu Cuomu,et al.Study on the Effects of Tibetan Medicine Puerna Extract on the Proliferation of Hela Cells in Cervical Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(08):18.[doi:10.12174/j.issn.2096-9600.2021.06.05]
[7]邓歌.放射疗法配合黄药子汤保留灌肠治疗晚期宫颈癌临床观察[J].西部中医药,2021,34(06):103.[doi:10.12174/j.issn.2096-9600.2021.06.25]
　DENG Ge.Clinical Observation of Radiotherapy Combined with Retention Enema with Huangyaozi Decoction in the Treatment of Advanced Cervical Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(08):103.[doi:10.12174/j.issn.2096-9600.2021.06.25]
[8]董姣姣,李楠,白俊,等.贺丰杰教授从气阴两虚论治宫颈癌术后患者临证经验拾萃[J].西部中医药,2021,34(04):57.[doi:10.12174/j.issn.2096-9600.2021.04.14]
　DONG Jiaojiao,LI Nan,BAI Jun,et al.Professor He Fengjie′s Clinical Experience in Discussing and Treating the Patients after the Operation of Cervical Cancer of Qi and Yin Deficiency Pattern[J].Western Journal of Traditional Chinese Medicine,2021,34(08):57.[doi:10.12174/j.issn.2096-9600.2021.04.14]
[9]印海娟,郑杰,董涛,等.复方苦参注射液联合新辅助化疗对宫颈癌患者CA125、CA199、CEA的影响[J].西部中医药,2021,34(04):105.[doi:10.12174/j.issn.2096-9600.2021.04.26]
　YIN Haijuan,ZHENG Jie,DONG Tao,et al.Effects of Compound Kushen Injection Combined with Neoadjuvant Chemotherapy on CA125, CA199 and CEA in Patients with Cervical Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(08):105.[doi:10.12174/j.issn.2096-9600.2021.04.26]

备注/Memo

备注/Memo:
收稿日期：2017-01-29*基金项目：国家自然科学基金(编号81260387)；甘肃省自然科学基金(编号1208RJZ109)。作者简介：曲波(1981—)，男，硕士学位，主治医师。研究方向：妇科肿瘤及内分泌疾病的诊治。△通讯作者：王海琳(1964—)，女，硕士学位，硕士研究生导师，教授，主任医师。研究方向：妇科肿瘤及内分泌疾病的诊治。
更新日期/Last Update: 2017-08-15